Core Viewpoint - The core management team and major shareholders of Everest Medicines (01952.HK) collectively purchased over HKD 38 million worth of company shares, signaling strong confidence in the company's future prospects [1][2][17]. Group 1: Share Purchase Details - Total amount of shares purchased exceeded HKD 38 million [1][17]. - Average purchase price was approximately HKD 45.01 per share [2][6]. - Key shareholders, including Kangqiao Capital, have committed to potentially increasing their stake by up to 1% over the next three to six months [2][24]. Group 2: Market Reaction and Management Confidence - Following the announcement of the share purchases, the company's stock price rose by over 4% on the next trading day [2][17]. - The board of directors stated that this action reflects the management's and major shareholders' confidence in the company's long-term development [2][23]. Group 3: Key Executive Involvement - Notable executives involved in the share purchase include CFO He Ying, who spent approximately RMB 4 million to acquire around 98,159 shares, representing about 16% of his annual salary of RMB 25 million [3][9][25]. - Other executives, including the chairman and CEO, also participated in the share buyback [5][21].
年薪2500万！CFO刚豪掷400万增持！